Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NPI5
UPID:
NRK2_HUMAN
Alternative names:
Integrin beta-1-binding protein 3; Muscle integrin-binding protein; Nicotinic acid riboside kinase 2; Ribosylnicotinamide kinase 2; Ribosylnicotinic acid kinase 2
Alternative UPACC:
Q9NPI5; B7ZKR3; Q52M81; Q9NZK3
Background:
Nicotinamide riboside kinase 2 (NRK2) plays a pivotal role in cellular metabolism by catalyzing the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR), leading to the formation of nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN). It also influences cell-matrix interactions by reducing laminin matrix deposition and cell adhesion to laminin. NRK2 is involved in the regulation of PXN protein levels and its tyrosine phosphorylation, and it may contribute to terminal myogenesis.
Therapeutic significance:
Understanding the role of Nicotinamide riboside kinase 2 could open doors to potential therapeutic strategies.